Strides Pharma Science posts net profit of ₹93.66 crore in Q2

The company had posted a net loss of ₹149.45 crore in the corresponding period last fiscal, Strides Pharma Science said in a regulatory filing.

Revenue from operations in the quarter under review stood at ₹1,201.11 crore as against ₹999.43 crore in the year-ago period, it added.

Total expenses in the second quarter were higher at ₹1,097.98 crore as compared to ₹984.99 crore in the same period a year ago.

Q2FY25 demonstrated sustained growth across all markets fuelled by new product launches. US operations reported the highest-ever quarterly revenue of $75 million in Q2FY25, Strides Pharma Science Founder & Executive Chairperson Arun Kumar, and MD & Group CEO Badree Komandur said.

Stock price performance

Strides Pharma Science Ltd shares opened a bit up today at ₹1563.10 per share on the NSE. Later in the day, the stock saw further profit booking and now running at ₹1531.40 apiece, down 1.85%.

About Strides Pharma Science Ltd

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company's pharmaceutical products are sold in over 100 countries. The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.